Skip to main content
. 2021 Jul 29;39(35):3959–3977. doi: 10.1200/JCO.21.01392

FIG 1.

FIG 1.

Algorithm for endocrine treatment and targeted therapy for HR-positive, HER2-negative MBC. aPatients receiving alpelisib should have laboratory and symptom monitoring weekly for the first 4 weeks of therapy to avoid serious toxicity. CDK, cyclin-dependent kinase; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MBC, metastatic breast cancer.